<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ibritumomab tiuxetan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ibritumomab tiuxetan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ibritumomab tiuxetan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10752" href="/d/html/10752.html" rel="external">see "Ibritumomab tiuxetan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708911"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infusion reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ibritumomab tiuxetan therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. Discontinue rituximab and Y-90 ibritumomab tiuxetan infusions in patients who develop severe infusion reactions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Prolonged and severe cytopenias:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Y-90 ibritumomab tiuxetan administration results in severe and prolonged cytopenias in most patients. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Severe cutaneous and mucocutaneous reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the ibritumomab tiuxetan therapeutic regimen. Discontinue rituximab and Y-90 ibritumomab tiuxetan infusions in patients experiencing severe cutaneous or mucocutaneous reactions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dosing:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The dose of Y-90 ibritumomab tiuxetan should not exceed 32 mCi (1,184 MBq).</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181392"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zevalin Y-90</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867156"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zevalin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181405"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD20;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F181395"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedicate with oral acetaminophen 650 mg and oral diphenhydramine 50 mg prior to <b>each</b> rituximab infusion. Allow at least 6 weeks, but no more than 12 weeks following first-line chemotherapy before treatment initiation; platelets should recover to ≥150,000/mm<sup>3</sup> prior to initiation of treatment regimen. Do not administer to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas:</b> Ibritumomab is administered <b>only</b> as part of the Zevalin therapeutic regimen (a combined treatment regimen with rituximab). The regimen consists of two steps:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Day 1:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rituximab:</i>
<b>IV:</b> 250 mg/m<sup>2</sup> at an initial rate of 50 mg/hour. If hypersensitivity or infusion-related events do not occur, increase infusion in increments of 50 mg/hour every 30 minutes, to a maximum of 400 mg/hour. Stop rituximab and discontinue regimen for severe infusion reaction. For less severe infusion reactions, temporarily slow or interrupt; the infusion may be resumed at one-half the previous rate upon improvement of symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Day 7, 8, or 9 of treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rituximab:</i>
<b>IV:</b> 250 mg/m<sup>2</sup> at an initial rate of 100 mg/hour (50 mg/hour if infusion-related events occurred with the day 1 infusion). If hypersensitivity or infusion-related events do not occur, increase infusion in increments of 100 mg/hour every 30 minutes, to a maximum of 400 mg/hour, as tolerated (increase in 50 mg/hour increments every 30 minutes if initial infusion rate was 50 mg/hour).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Y-90 ibritumomab (within 4 hours after completion of the rituximab infusion):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Platelet count ≥150,000 cells/mm<sup>3</sup>: <b>IV: </b>0.4 mCi/kg (14.8 MBq/kg) actual body weight over 10 minutes; maximum dose: 32 mCi (1184 MBq).</p>
<p style="text-indent:-2em;margin-left:6em;">Platelet count between 100,000 to 149,000 cells/mm<sup>3</sup> (in relapsed or refractory patients): <b>IV: </b>0.3 mCi/kg (11.1 MBq/kg) actual body weight over 10 minutes; maximum dose: 32 mCi (1184 MBq).</p>
<p style="text-indent:-2em;margin-left:6em;">Platelet count &lt;100,000 cells/mm<sup>3</sup>: Do <b>not</b> administer.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maximum dose:</b> The prescribed, measured, and administered dose of Y-90 ibritumomab must not exceed 32 mCi (1184 MBq), regardless of the patient's body weight.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990947"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988280"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F57067995"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Cutaneous or mucocutaneous skin reactions, severe:</i> Discontinue rituximab and ibritumomab tiuxetan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Infusion reactions:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Severe infusion reaction: Immediately stop rituximab infusion and discontinue ibritumomab tiuxetan therapeutic regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Less severe reactions: Temporarily slow or interrupt rituximab infusion; if symptoms improve, the rituximab infusion may be resumed/continued at one-half the previous rate.</p></div>
<div class="block doe drugH1Div" id="F3062779"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F181364"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and include the use of concomitant rituximab.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17%), diarrhea (11%), nausea (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (22% to 61%; grades 3/4: 5% to 17%), leukopenia (43%; grades 3/4: 36%), lymphocytopenia (26%; grades 3/4: 18%), malignant neoplasm (secondary) (13%), neutropenia (45% to 77%; grades 3/4: 41% to 60%), thrombocytopenia (62% to 95%; grades 3/4: 51% to 63%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (within first 3 months: 29%; serious infection: 1% to 3%; 3 months to 4 years after treatment: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (15%), fatigue (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (11%), nasopharyngitis (19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymosis (7%), night sweats (8%), pruritus (7%), skin rash (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute myelocytic leukemia (≤5%), myelodysplastic syndrome (≤5%), petechia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (HAMA/HACA: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (8%), epistaxis (5%), flu-like symptoms (8%), pharyngolaryngeal pain (7%), rhinitis (8%), sinusitis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Radiation injury (delayed [~1 month]; in tissues in or near areas of lymphomatous involvement)</p></div>
<div class="block coi drugH1Div" id="F181376"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed within the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known type I hypersensitivity or anaphylactic reaction to ibritumomab tiuxetan, murine proteins, or any component of the formulation, including yttrium chloride and rituximab; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F181362"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe, delayed, and prolonged cytopenias (thrombocytopenia and neutropenia) commonly occur. The median platelet, ANC, and hemoglobin nadir occurred at 49 to 53 days, 61 to 62 days, and 68 to 69 days, respectively. Cytopenias may persist beyond 12 weeks. The median duration of thrombocytopenia and neutropenia was 24 to 35 days and 22 to 29 days respectively, and the median time to platelet and ANC recovery was 13 to 14 days and 12 to 15 days, respectively. Patients with mild baseline thrombocytopenia (100,000 to 149,000/mm<sup>3</sup>) may experience higher incidences of severe neutropenia and thrombocytopenia. Hemorrhage may occur due to thrombocytopenia; avoid concomitant use of medications interfering with coagulation or platelet function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous/mucocutaneous reactions: Severe cutaneous and mucocutaneous skin reactions may occur with ibritumomab tiuxetan (some fatal). Reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, and exfoliative dermatitis. Onset may occur within days to 4 months following infusion. Discontinue rituximab and ibritumomab tiuxetan in patients experiencing severe cutaneous or mucocutaneous skin reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation/radiation necrosis: Irritant with vesicant-like properties; avoid extravasation. Infusion site erythema and ulceration have been reported following extravasation; monitor infusion site; promptly terminate infusion with symptoms/signs of extravasation (restart in another limb). There is a case report of (delayed) erythema and ulceration, which is described as radiation necrosis following yttrium-90-ibritumomab extravasation (Williams 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ibritumomab tiuxetan therapeutic regimen; these fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most fatalities occurred with the initial rituximab infusion (onset within 30 to 120 minutes). Other reactions may include hypotension, angioedema, bronchospasm, and urticaria. Administer in a facility with immediate access to resuscitative measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation injury: Delayed (up to 1 month) radiation injury has occurred in or near areas of lymphomatous involvement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Malignancies due to the radiation dose from therapeutic exposure may occur. Secondary malignancies (acute myelogenous leukemia and/or myelodysplastic syndrome) have been reported; the median time to secondary malignancy diagnosis following ibritumomab treatment was 1.9 years with a range of 0.4 to 6.3 years (Czuczman 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Product contains albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. The contents of the kit are not radioactive until radiolabeling occurs. During and after radiolabeling, adequate shielding should be used with this product, minimize radiation exposure (to patient and health care professionals) in accordance with institutional radiation safety practices.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Do not administer live viral vaccines to patients who have recently received ibritumomab treatment. The safety of immunization with live vaccines following ibritumomab therapy has not been studied; the ability to generate a response to any vaccine after receiving treatment has not been studied.</p></div>
<div class="block foc drugH1Div" id="F181371"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zevalin Y-90: 3.2 mg/2 mL [contains albumin human]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zevalin Y-90: 3.2 mg/2 mL [DSC] [pyrogen free; contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F181359"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323189"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Zevalin Y-90 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.2 mg/2 mL (per each): $74,124.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867157"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zevalin: 3.2 mg/2 mL [contains albumin human]</p></div>
<div class="block adm drugH1Div" id="F181373"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Rituximab: Administer the first infusion of rituximab at an initial rate of 50 mg/hour. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hour increments every 30 minutes, to a maximum of 400 mg/hour. Immediately stop infusion for severe infusion reaction (discontinue ibritumomab regimen); less severe reactions may be managed by slowing or interrupting infusion. For less severe reactions, infusion may continue at one-half the previous rate upon improvement of patient symptoms. If infusion reaction did not occur in initial rituximab infusion, subsequent rituximab infusion can be administered at an initial rate of 100 mg/hour and increased in 100 mg/hour increments at 30-minute intervals, to a maximum of 400 mg/hour as tolerated. If infusion reaction occurred with initial rituximab infusion, initiate at 50 mg/hour with increases of 50 mg/hour increments every 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Y-90 ibritumomab: Begin within 4 hours of completion of rituximab infusion. Inject slowly, over 10 minutes through a 0.22 micron low protein binding in-line filter (filter placed between syringe and infusion port) into a free-flowing IV line. After injection, flush line with at least 10 mL normal saline.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant with vesicant-like properties; avoid extravasation. Ensure proper needle or catheter position prior to administration. Closely monitor infusion site. If signs or symptoms of extravasation occur, stop infusion and restart in another limb.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block use drugH1Div" id="F181372"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Non-Hodgkin lymphomas:</b> Treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL) in adults; treatment of previously untreated follicular NHL in adults who achieve a partial or complete response to first-line chemotherapy.</p></div>
<div class="block mst drugH1Div" id="F3401646"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ibritumomab tiuxetan may be confused with ibrutinib and inotuzumab ozogamicin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299501"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F181366"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: May enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of anti-CD20 B-cell depleting therapy is reduced. Anti-CD20 B-Cell Depleting Therapies may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Administer COVID-19 vaccine 2 to 4 weeks prior to the next scheduled dose of anti-CD20 therapy, if used chronically for the treatment of autoimmune disease. Revaccinate 6 months after completion of anti-CD20 therapy if used over a limited period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307633"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to therapy in patients who could become pregnant. Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during therapy and for 12 months following the last ibritumomab tiuxetan dose.</p></div>
<div class="block pri drugH1Div" id="F181378"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the radioactivity, Y-90 ibritumomab may cause fetal harm if administered during pregnancy. In addition, ibritumomab tiuxetan is a humanized monoclonal antibody (IgG<sub>1</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F181379"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ibritumomab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Because many immunoglobulins are present in milk, excretion of ibritumomab tiuxetan is expected. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that lactating patients avoid breastfeeding during therapy and for 6 months following the last ibritumomab tiuxetan dose.</p></div>
<div class="block mop drugH1Div" id="F181369"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet counts weekly until recovery, or as clinically indicated. Platelet count must be obtained prior to day 7, 8, or 9; monitor for cytopenias (and related complications such as febrile neutropenia or hemorrhage) for up to 3 months after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs of active hepatitis B infection (during and for up to 12 months after therapy completion). Monitor for infusion-related allergic reactions (typically within 30 to 120 minutes of administration), for extravasation during ibritumomab infusion; and for severe cutaneous and mucocutaneous reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F181361"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ibritumomab is a monoclonal antibody directed against the CD20 antigen found on pre-B and mature B lymphocytes (normal and malignant). Ibritumomab binding induces apoptosis in B lymphocytes <i>in vitro</i>. It is combined with the chelator tiuxetan, which acts as a specific chelation site for Yttrium-90 (Y-90). The monoclonal antibody acts as a delivery system to direct the radioactive isotope to the targeted cells, however, binding has been observed in lymphoid cells throughout the body and in lymphoid nodules in organs such as the large and small intestines. Beta-emission induces cellular damage through the formation of free radicals (in both target cells and surrounding cells).</p></div>
<div class="block phk drugH1Div" id="F181375"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: B cell recovery begins in ~12 weeks; generally in normal range within 9 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: To lymphoid cells throughout the body and in lymphoid nodules in organs such as the large and small intestines, spleen, testes, and liver.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Y-90 ibritumomab: 30 hours; Yttrium-90 decays with a physical half-life of 64 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: A median of 7.2% of the radiolabeled activity was excreted in urine over 7 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539878"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zevamab</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zevalin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12393555">
<a name="12393555"></a>Cheson BD, “Radioimmunotherapy of Non-Hodgkin Lymphomas,” <i>Blood</i>, 2003, 101(2):391-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12393555/pubmed" id="12393555" target="_blank">12393555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17709799">
<a name="17709799"></a>Czuczman MS, Emmanouilides C, Darif M, et al, “Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy,” <i>J Clin Oncol</i>, 2007, 25(27):4285-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/17709799/pubmed" id="17709799" target="_blank">17709799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15016644">
<a name="15016644"></a>Gordon LI, Molina A, Witzig T, et al, “Durable Responses after Ibritumomab Tiuxetan Radioimmunotherapy for CD20+ B-Cell Lymphoma: Long-Term Follow-Up of a Phase 1/2 Study,” <i>Blood</i>, 2004, 103(12):4429-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/15016644/pubmed" id="15016644" target="_blank">15016644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22586182">
<a name="22586182"></a>Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90-yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. <i>Blood</i>. 2012;119(26):6373-6378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/22586182/pubmed" id="22586182" target="_blank">22586182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18854568">
<a name="18854568"></a>Morschhauser F, Radford J, Van Hoof A, et al, “Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma,” <i>J Clin Oncol</i>, 2008, 26(32):5156-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/18854568/pubmed" id="18854568" target="_blank">18854568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23547079">
<a name="23547079"></a>Morschhauser F, Radford J, Van Hoof A, et al. 90-Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. <i>J Clin Oncol</i>. 2013;31(16):1977-1983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/23547079/pubmed" id="23547079" target="_blank">23547079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16706630">
<a name="16706630"></a>Williams G, Palmer MR, Parker JA, et al, “Extravasation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case Report,” <i>Cancer Biother Radiopharm</i>, 2006, 21(2):101-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/16706630/pubmed" id="16706630" target="_blank">16706630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011122">
<a name="12011122"></a>Witzig TE, Gordon LI, Cabanillas F, et al, “Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma,” <i>J Clin Oncol</i>, 2002, 20(10):2453-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12011122/pubmed" id="12011122" target="_blank">12011122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12663713">
<a name="12663713"></a>Witzig TE, White CA, Gordon LI, et al, “Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma,” <i>J Clin Oncol</i>, 2003, 21(7):1263-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/12663713/pubmed" id="12663713" target="_blank">12663713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10577851">
<a name="10577851"></a>Witzig TE, White CA, Wiseman GA, et al, “Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20(+) B-Cell Non-Hodgkin's Lymphoma,” <i>J Clin Oncol</i>, 1999, 17(12):3793-803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibritumomab-tiuxetan-drug-information/abstract-text/10577851/pubmed" id="10577851" target="_blank">10577851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zevalin.1">
<a name="Zevalin.1"></a>Zevalin (ibritumomab) [prescribing information]. East Windsor, NJ: Acrotech Biopharma LLC; April 2023.</div>
</li>
<li>
<div class="reference">
                  Zevalin (ibritumomab) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc; September 2017.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8709 Version 246.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
